CR9477A - Numero de copias del gen del receptor del factor de crecimiento epidermico - Google Patents

Numero de copias del gen del receptor del factor de crecimiento epidermico

Info

Publication number
CR9477A
CR9477A CR9477A CR9477A CR9477A CR 9477 A CR9477 A CR 9477A CR 9477 A CR9477 A CR 9477A CR 9477 A CR9477 A CR 9477A CR 9477 A CR9477 A CR 9477A
Authority
CR
Costa Rica
Prior art keywords
growth factor
epidermal growth
gen
copies number
factor receiver
Prior art date
Application number
CR9477A
Other languages
English (en)
Inventor
Salvatore Siena
Mauro Moroni
Alberto Bardelli
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR9477A publication Critical patent/CR9477A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen los metodos para predecir si un tratamiento con el agente de enlace especifico anti-receptor del factor de crecimiento epidermico (EGFR) sera eficaz en el tratamiento del cancer y los metodos de tratamiento de los pacientes con agentes de enlace especificos anti-EGFR.
CR9477A 2005-04-01 2007-10-26 Numero de copias del gen del receptor del factor de crecimiento epidermico CR9477A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66782705P 2005-04-01 2005-04-01

Publications (1)

Publication Number Publication Date
CR9477A true CR9477A (es) 2008-03-07

Family

ID=36917385

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9477A CR9477A (es) 2005-04-01 2007-10-26 Numero de copias del gen del receptor del factor de crecimiento epidermico

Country Status (14)

Country Link
US (1) US7635570B2 (es)
EP (1) EP1869220A2 (es)
JP (1) JP2008536493A (es)
KR (1) KR20080014745A (es)
CN (1) CN102007220A (es)
AU (1) AU2006232378A1 (es)
BR (1) BRPI0609615A2 (es)
CA (1) CA2602619A1 (es)
CR (1) CR9477A (es)
EA (1) EA200702143A1 (es)
IL (1) IL186139A0 (es)
MX (1) MX2007012074A (es)
NO (1) NO20074817L (es)
WO (1) WO2006107854A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030007640A (ko) * 2000-05-19 2003-01-23 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
AU2006233675A1 (en) * 2005-04-14 2006-10-19 Merck Patent Gmbh Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
CN104043123B (zh) 2007-01-25 2019-08-13 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CA2680330A1 (en) * 2007-03-13 2008-09-18 Alberto Bardelli K-ras and b-raf mutations and anti-egfr antibody therapy
TW200902553A (en) 2007-03-13 2009-01-16 Amgen Inc K-ras mutations and anti-EGFr antibody therapy
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
WO2009150255A2 (en) * 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
WO2010028288A2 (en) * 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
CN101899504B (zh) * 2010-05-11 2014-12-10 合肥艾迪康临床检验所有限公司 用于检测egfr基因拷贝数和7号染色体倍性的试剂
US9646134B2 (en) * 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
KR101952965B1 (ko) 2010-05-25 2019-02-27 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
DE102010060964A1 (de) * 2010-12-02 2012-06-06 Universitätsklinikum Hamburg-Eppendorf Verfahren zur Prädikation der therapeutischen Wirksamkeit von EGFR-Inhibitoren
SG194111A1 (en) 2011-04-07 2013-11-29 Amgen Inc Novel egfr binding proteins
ES2633183T3 (es) * 2011-12-30 2017-09-19 Abbott Molecular Inc. Materiales y procedimientos para el diagnóstico, pronóstico y evaluación del tratamiento terapéutico/profiláctico del cáncer de próstata
GB201223025D0 (en) * 2012-12-20 2013-02-06 Medizinische Universitaet Graz Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients
JP2016512032A (ja) 2013-03-14 2016-04-25 アボツト・モレキユラー・インコーポレイテツド 結腸直腸腺腫を評価するための材料および方法
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
WO2021097464A1 (en) * 2019-11-15 2021-05-20 Institute For Cancer Research Compositions and methods for regulating egfr amplification in cancer cells for improving egfr-targeted anti-cancer agent
CN112430646A (zh) * 2020-12-11 2021-03-02 南京求臻基因科技有限公司 一种基于数字pcr平台的egfr基因扩增的检测方法
CN112646893A (zh) * 2021-01-08 2021-04-13 北京泛生子基因科技有限公司 一种egfr基因拷贝数检测试剂盒及检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
WO2004111273A2 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP2949764B1 (en) * 2004-05-27 2018-04-11 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
AU2006233675A1 (en) * 2005-04-14 2006-10-19 Merck Patent Gmbh Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
WO2007001868A1 (en) 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations

Also Published As

Publication number Publication date
IL186139A0 (en) 2008-01-20
EA200702143A1 (ru) 2008-06-30
US20070087394A1 (en) 2007-04-19
CA2602619A1 (en) 2006-10-12
NO20074817L (no) 2007-12-28
CN102007220A (zh) 2011-04-06
KR20080014745A (ko) 2008-02-14
MX2007012074A (es) 2007-11-21
BRPI0609615A2 (pt) 2010-04-27
WO2006107854A2 (en) 2006-10-12
AU2006232378A1 (en) 2006-10-12
WO2006107854A3 (en) 2007-01-11
EP1869220A2 (en) 2007-12-26
US7635570B2 (en) 2009-12-22
JP2008536493A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
CR9477A (es) Numero de copias del gen del receptor del factor de crecimiento epidermico
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
MX2010001378A (es) Uso terapeutico de anticuerpos del receptor anti-tweak.
TW200612918A (en) Lonidamine analogs
TW200501960A (en) Synergistic kits and compositions for treating cancer
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
MX2019015200A (es) Compuestos de diarilhidantoina.
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
IL179095A0 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
DOP2011000002A (es) Agentes de fijación al receptor notch1 y metodos de uso de los mismos
CY1115333T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
MXPA04011550A (es) Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
EP1968981A4 (en) METHOD FOR TREATING TUMORS WITH AZAXANTHONES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)